Clinical-stage biopharmaceutical company Omeros has reported encouraging data from the single ascending dose (SAD) study portion of its Phase I trial of cognitive disorder drug OMS824.

OMS824 inhibits the enzyme PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia.

Omeros chairman and CEO Dr Gregory Demopulos said the company intends to complete the Phase I trial and commence studies in schizophrenia patients.

"While preparing for the next set of OMS824 studies, our pipeline continues to advance toward additional near-term milestones – Phase III data for OMS103HP this month, an NDA submission next quarter and, for as many as three additional programs, entry into the clinic in 2013," Demopulos said.

OMS824 was well-tolerated in the SAD study in which expected pharmacological effects were established in healthy subjects.

The study demonstrated linear pharmacokinetics, a long half-life consistent with once-daily dosing and good systemic exposure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has advanced OMS824 into next stage of the Phase I trial to evaluate the multiple-dose administration of the compound.

Complete data from the study is expected in 2013.